Abstract. Equine protozoal myeloencephalitis (EPM) is a neurological disease of horses and ponies caused by the apicomplexan protozoan parasite Sarcocystis neurona. The purposes of this study were to develop the most stringent criteria possible for a positive test result, to estimate the sensitivity and specificity of the EPM Western blot antibody test, and to assess the ability of bovine antibodies to Sarcocystis cruzi to act as a blocking agent to minimize false-positive results in the western blot test for S. neurona. Sarcocystis neurona merozoites harvested from equine dermal cell culture were heat denatured, and the proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in a 12-20% linear gradient gel. Separated proteins were electrophoretically transferred to polyvinylidene fluoride membranes and blocked in 1% bovine serum albumin and 0.5% Tween-Tris-buffered saline. Serum samples from 6 horses with S. neurona infections (confirmed by culture from neural tissue) and 57 horses without infections (horses from the Eastern Hemisphere, where S. neurona does not exist) were tested by Western blot. Horses from both groups had reactivity to the 62-, 30-, 16-, 13-, 11-, 10.5-, and 10-kD bands. Testing was repeated with another step. Blots were treated with bovine S. cruzi antibodies prior to loading the equine samples. After this modification of the Western blot test, positive infection status was significantly associated with reactivity to the 30-and 16-kD bands (P Ͻ 0.001, Fisher's exact test). The S. cruzi antibody-blocked Western blot had a sample sensitivity of 100% and sample specificity of 98%. It is concluded that the specificity of the Western blot test is improved by blocking proteins not specific to S. neurona and using reactivity to the 30-and 16-kD bands as the criterion for a positive test.
Equine protozoal myeloencephalitis (EPM) is a neurological disease of horses and ponies. Clinical signs of EPM may include incoordination, loss of proprioception, muscle wasting and weakness, and, in severe cases, recumbancy and death. 16 The etiologic agent of EPM has been demonstrated to be Sarcocystis neurona; 4, 5, 9 however, a similar neurological disease has been described in 2 horses from which Neospora species have been isolated. 3, 14, 15 Additional cases of EPM due to Neospora species must be reported before Neospora can be considered a similarly important etiologic agent of neurological disease in horses.
Sarcocystis species are obligate, heteroxenous coccidia. They reproduce asexually in an intermediate host, forming tissue cysts that are infective to a carnivorous definitive host when the intermediate host is consumed as prey or carrion. The parasite undergoes sexual reproduction in the intestine of the definitive host. Infective sporocysts are passed into the environ-ment in the feces of the definitive host. The life cycle begins anew when the sporocysts are consumed by an appropriate intermediate host, either in feces or in food or water that has been contaminated with fecal material. Sarcocystis species are usually specific to their definitive hosts; most cannot complete their life cycle in more than one species of carnivore. 13 Recent evidence showed that S. neurona utilizes the opossum (Didelphis virginiana) as its definitive host. 5, 7, 8 Horses and ponies can become infected by ingesting sporocysts of S. neurona, but S. neurona does not form mature tissue cysts in equids; equids are considered to be dead end hosts. 4 If the parasite enters the central nervous system of the horse, neurological disease can develop. To date, no EPM case has been reported in a horse that has not originated from the Western Hemisphere or traveled to the Americas. This phenomenon is because of the definitive host specificity of S. neurona; EPM does not occur in native equids living outside the range of the opossum. 6 Currently, the only method to establish a definitive diagnosis of EPM is by postmortem examination. By histologic examination, the parasite may be found in inflammatory lesions in white and gray matter. The sensitivity of this technique may be enhanced with immunohistochemistry. In a study that compared the efficacy of hematoxylin and eosin (HE) staining with the avidin-biotin complex (ABC) immunoperoxidase method of staining of neural tissues of suspected EPM cases, the ABC technique was more effective. 11 The HE method detected the parasite in 20% of the suspected cases. The ABC method was employed with both S. neurona and Sarcocystis cruzi antibodies. The S. cruzi antibodies detected the parasite in 67% of the suspect cases, and the S. neurona antibodies detected it in 51% of them, suggesting that antibody cross-reactivity was significant.
Cross-reactivity in antibodies directed against Sarcocystis species has been utilized for antemortem diagnosis of EPM. Diagnostic testing can be performed with an indirect fluorescent antibody (IFA) titer that measures a sample's antibody reactivity to S. cruzi as a nonspecific Sarcocystis titer. e The S. cruzi IFA test was the first antemortem EPM test available, but it cannot distinguish between antibodies specific to S. neurona and antibodies specific to S. cruzi.
In 1993, a Western blot test was developed to detect antibodies to S. neurona-specific antigens (approximately 22, 13, and 10.5 kD) in serum and cerebrospinal fluid (CSF) of horses suspected of having EPM. 10 In 1997, a different criterion was used by the same laboratory in the only published experimental infection study of S. neurona in horses. In that study, reactivity to proteins of approximately 13, 11, 10.5, and 10 kD constituted a positive test. 7 Recent work indicates that immunodominant proteins of approximately 29 and 17 kD are specific to S. neurona, which suggests a different criterion for a positive test than that reported previously. 12, 14 The purposes of this study were to develop the most stringent criteria possible for a positive test result, to estimate the sensitivity and specificity of the EPM Western blot antibody assay, and to test the ability of bovine antibodies to S. cruzi to act as a blocking agent to prevent false-positive results in the Western blot test for S. neurona.
Materials and methods
Selection of samples. Equine serum samples were selected on the basis of the probability that they would or would not contain specific antibodies to S. neurona. Serum samples from 6 horses from which S. neurona was cultured postmortem were defined as true positives because they were highly likely to possess antibodies to S. neurona. Forty-five native equine serum samples were obtained from 1 farm in India and 12 from 1 farm in Hanover, Germany, where opossums and S. neurona are not known to exist. These samples were defined as true negatives on the basis of the low probability that the horses could possess antibodies to S. neurona.
Western blot testing. Sarcocystis neurona merozoites were harvested from equine dermal cell culture and heat denatured in sample buffer (0.5 M Tris, pH 7.4, with 10% sodium dodecyl sulfate, 20% glycerol, and 5% ␤-mercaptoethanol). Denatured proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in 12-20% linear gradient gels with a 4% stacking gel. For reference purposes, biotinylated broad-range molecular weight size standard markers a were run on each gel. Separated proteins were electrophoretically transferred to polyvinylidene fluoride membranes h and blocked overnight in blocking buffer (1% bovine serum albumen in 0.5% Tween-Tris buffered saline [TTBS] ). Blots were air-dried and frozen for later use. For testing of serum samples, the blots were wetted in TTBS and clamped in a slot blot apparatus. a Molecular weight markers were covered with blocking buffer in the first 2 lanes; the remaining 18 lanes were loaded with serum samples diluted 1:10 in blocking buffer and incubated overnight. Subsequently, the sample lanes were washed 3 times in TTBS and incubated for 3 hr in blocking buffer with biotin-labeled goat anti-horse IgG(HϩL). f The sample lanes and the molecular weight marker lanes were then washed 3 times in TTBS, incubated in TTBS with avidin-peroxidase conjugate c for 1 hr, washed 3 times in TTBS, and developed with aminoethyl carbazole substrate. A regression was calculated for the logtransformed protein marker size versus relative protein marker migration, and molecular weights of unknown proteins were extrapolated from the trendline.
Bovine S. cruzi antibody treatment. The Western blot protocol was repeated with an additional treatment. The blots were incubated with fractionated IgG b (ϳ25 mg/ml in Trisbuffered saline, pH 7.4) from cattle that tested as high positives (fluorescent immunoassay system d values of Ͼ200) for S. cruzi e diluted 1:65 in blocking buffer for 1.5 hr. Then the blots were loaded with equine samples and developed according to the previously described protocol.
Bovine controls. Bovine S. cruzi IgG was tested by the Western blot protocol described above, at a dilution of 1:65, with biotin-labeled goat anti-equine IgG(HϩL) f to verify that anti-equine IgG would not bind to bovine IgG. Additionally, the bovine IgG was tested on an untreated blot and developed with biotin-labeled goat anti-bovine IgG(HϩL) f to determine which S. neurona antigens are detected by S. cruzipositive cattle.
Data analysis. Samples were tested with and without the bovine S. cruzi antibody treatment. The protein bands detected by each sample were recorded and tested, alone and in combination with others, by the Fisher's exact test for independence (2-tailed). g A P-value of 0.05 or less was considered to be significant. The band or combination of bands that was most strongly associated with a positive test was used to classify samples as test positives and test negatives. These totals were compared with the correct classification of true positives and true negatives. Test sensitivity, test specificity, and predictive values were calculated by standard formulae. 17 
Results
Data analysis. The immunodominant proteins detected by the positive and negative samples in this study are listed in Table 1 . When tested by Western blot without the bovine S. cruzi antibodies, no single band was significant by the Fisher's exact test. This was also true of combinations of bands. Reactivity to proteins at 62, 30, 21, 16, 13, 11, 10.5, and 10 kD was seen in all the culture-confirmed positive samples and in the majority of the true-negative samples (Fig. 1) . No diagnostic criterion could be developed from these test results.
Analysis of the proteins detected by the true-positive and true-negative samples on the bovine S. cruzi IgG-treated blots showed the combined presence of the 30-and 16-kD bands to be strongly associated by the Fisher's exact test (P Ͻ 0.001) with a positive test result. All of the culture-confirmed positive samples exhibited both bands (Fig. 1) . Of the 57 true negatives, 56 tested negative by this criterion (Fig. 1) . One sample collected from a horse in India produced bands near enough to 30 and 16 kD to be interpreted as suspect positive. For the purposes of our analysis, that sample was classified as a false positive.
The diagnostic criterion of simultaneous reactivity against the 30-and 16-kD bands used on bovine S. cruzi IgG-treated blots was compared with the true status of the samples. These results are shown in Table  2 . Because the culture-confirmed positive samples were all correctly identified, the test sensitivity was estimated to be approaching 100%. Of the 57 true negatives, 56 were correctly identified, thus the test specificity was estimated to be approximately 98%. With the presence or absence of S. neurona-specific antibodies as the outcome of interest, the sample positive predictive value was 86%, and the sample negative predictive value was 100%.
Bovine controls. The bovine S. cruzi antibody detected proteins at approximately 56, 46, 31, 25, 22, 17, and 6 kD on an S. neurona blot that was not preincubated with S. cruzi antibody (Fig. 1) . The bovine control sample on a treated blot showed that the antibody-blocking technique did not give a false-positive result (Fig. 1) .
Discussion
This study supports work by others that suggested that the best criterion for a positive S. neurona immunoblot test is antibody reactivity to immunodominant proteins at approximately 30 and 16 kD. 12, 14 The culture-confirmed S. neurona true-positive serum samples used in this analysis were highly consistent in their reactivity to those specific proteins. The results of this study also demonstrate that the Western blot S. neurona antibody test can be subject to false-positive results because of antibody cross-reactivity. On untreated blots in these experiments, the true-negative samples detected proteins at 30 and 16 kD as well as at 13, 11, 10.5, and 10 kD. In previous studies, all of these proteins have been proposed as specific to S. neurona, 10,12,14 therefore, S. neurona Western blot antibody tests that do not remove nonspecific cross-reactivity are not reliable for use on serum. In this study, no statistically significant positive criterion could be developed from the untreated blots.
Exposing S. neurona immunoblots to bovine S. cruzi IgG prior to testing equine samples proved to be an effective technique for reducing false-positive test results. The bovine S. cruzi antibodies bind to Sarcocystis genus-specific proteins but not to S. neuronaspecific proteins. By blocking the nonspecific proteins that may be too close to discern from the specific proteins with the naked eye, blot reading and interpretation are improved.
The sensitivity and specificity of the modified Western blot test were high in this small data set. It is likely that as this research continues the estimates may drop. For example, it is possible that a horse from which S. neurona is cultured will not have antibodies directed against the immunodominant proteins at 30 and 16 kD. A false negative such as this could be because of an acute onset of EPM, which has not allowed the animal sufficient time to mount a detectable antibody response. In a clinical diagnostic setting, testing of samples from horses from around the USA by the Michigan State University Animal Health Diagnostic Laboratory suggests that the protein at 30 kD may be detected before the protein at 16 kD during the course of seroconversion. Until the progression of seroconversion can be described, horses with acute clinical signs consistent with EPM whose immunoblot test detects the 30-kD band alone should be retested after 7-10 days to confirm the antibody status of the animal. Another potential source of a false-negative test might result from a latent stage of S. neurona that would not stimulate an antibody response. Finally, the true-negative samples from India and Germany had many cross-reactive antibodies, but further testing of sera from Eastern Hemisphere equids may reveal new possible sources of false-positive test results.
Despite these sources of potential test error, the positive criterion and the S. cruzi antibody-blocking technique described here improved the specificity of the Western blot antibody test for S. neurona without any concurrent loss of sensitivity. Although the number of culture-confirmed positive samples in this study is small, they represent a highly stringent ''gold standard.'' It is noteworthy that of the 9 horses from which S. neurona has been cultured at Michigan State University, 2 had clinical signs and pathologic lesions consistent with other neurological diseases. This finding suggests that S. neurona may exist in a subclinical or latent state in some horses (unpublished observations). Without successfully culturing S. neurona from these animals, it would have been logical to conclude that these horses had false-positive test results for S. neurona.
In a clinical diagnostic setting, S. neurona Western blot test results require careful interpretation. Even with an improved serum test, CSF testing is still preferred to determine if the parasite has gained access to the central nervous system. CSF from the true-positive horses in this study has been tested by the S. cruzitreated western blot assay described here. CSF was available from 8 culture-confirmed horses, and all detected the 30-and 16-kD antigens; 4 of them also reacted to 13-kD antigens. Because of unavailability of CSF samples from horses that met the criteria for true negatives, CSF could not be included in this study. Acquisition of those samples in under way. Although a positive CSF test is necessary to confirm that the parasite has been present in the central nervous system, a more specific serum test is useful for making the decision to perform a spinal tap because a negative result would usually rule out EPM. Further, the modified Western blot shows promise as a research tool. The original western blot test 10 has been used to estimate the seroprevalence of antibodies to S. neurona in neurologically normal horses residing in Pennsylvania, 1 Ohio, 18 and Oregon. 2 Seroprevalance estimates ranged from 22% to 65% for various geographic regions sampled, indicating high rates of infection with S. neurona in neurologically normal horses. If these studies were based on a test with significant crossreactivity, the serum antibody prevalence may have been overestimated. A more accurate serum test will allow epidemiologists to make more precise estimates of seroprevalence and the risk factors associated with infection.
Finally, by classifying true positives and true negatives according to antibody status, rather than by clinical diagnosis of EPM or other neurological diseases, it is possible to evaluate the test solely by its ability to detect the desired antibodies. There is some confusion about how to interpret positive CSF samples from neurologically normal horses. Often, such results are called ''false positives'' because they are not predictive of disease. However, if the test is accurately detecting S. neurona antibodies, other explanations for their presence in CSF must be sought because ruling out subclinical infections in these cases is difficult. Additional studies will be required to determine the association of CSF antibodies to S. neurona with the actual presence of the parasite and, ultimately, the association of the presence of S. neurona with clinical EPM.
